SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin declines on recalling 17,814 bottles of Cefprozil in US market

26 Apr 2021 Evaluate

Lupin is currently trading at Rs. 1063.05, down by 15.95 points or 1.48% from its previous closing of Rs. 1079.00 on the BSE.

The scrip opened at Rs. 1073.00 and has touched a high and low of Rs. 1080.60 and Rs. 1057.05 respectively. So far 89449 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 808.50 on 07-May-2020.

Last one week high and low of the scrip stood at Rs. 1106.35 and Rs. 1030.00 respectively. The current market cap of the company is Rs. 48264.76 crore.

The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 40.46% and 12.69% respectively.

Lupin is recalling 17,814 bottles of Cefprozil for Oral Suspension USP, a second-generation antibiotic used to treat ear infections, skin infections, and other bacterial infections in US market. According to the USFDA, the company is recalling the affected lot for being ‘Superpotent’.

The affected lot has been manufactured at Lupin's Mandideep plant in Madhya Pradesh and distributed in the US by Baltimore-based Lupin Pharmaceuticals Inc. Lupin initiated the Class II voluntary recall across the US and Puerto Rico on March 26 this year.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2255.65 -122.25 (-5.14%)
11-May-2026 15:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1873.00
Dr. Reddys Lab 1278.40
Cipla 1305.40
Zydus Lifesciences 957.35
Lupin 2255.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×